MARKET WIREYahoo Finance UK • 8h ago
Aura Biosciences, Inc. (AURA) Seasonal returns chartYahoo Finance UK report covering Aura Biosciences Inc. (AURA) market action, institutional positioning, and fundamental catalysts.
Why AURA Stock dropped -2.46% Today — RQD Quant Desk Flash
$6.14 -2.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $6.10
Aura Biosciences Inc. (AURA) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $652.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AURA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Aura Biosciences Inc. (NASDAQ: AURA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $6.14 (-2.46% 1D, market cap $652.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AURA ranks #803 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AURA compare to SLBT and DBVT in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AURA carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SLBT (SL Science Holding Limited) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $656.1M) and DBVT (DBV Technologies S.A.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $647.0M). Among the 5-stock peer group, AURA leads on earnings multiple (N/A) while AURA leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AURA?
▼
Per AURA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001501796), Aura Biosciences Inc. generated $0 in revenue, -$106.2M in net income, and -$85.2M in free cash flow against $169.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $6.10 (-0.63%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AURA)Realized 20D OHLCV Swing Band: ±9.4%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY AURA SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (23% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$6.54-3.8% Next Q
39
Q2 (-2Q)Grade E$6.29-1.7% Next Q
36
Q3 (-1Q)Grade E$6.18-0.6% Next Q
34
CurrentGrade E$6.14-9.4% Hist 90D α
31
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a AURA Turnaround Squeeze
While AURA currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.65) and Max Pain ($6.45) forces dealer call-delta covering toward $10.01.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AURA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AURA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AURA Stock dropped -2.46% Today — RQD Quant Desk Flash
Aura Biosciences Inc. (AURA) dropped -2.46% to $6.14, trading at 29% of its 52-week range ($4.73 – $9.53). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 29% of its 52-week range ($4.73 – $9.53) with RSI-14 at 47.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.4% around $6.14 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live AURA Headlines & Catalysts
MARKET WIRESeeking Alpha • 11h ago
Aura Biosciences: A Pivotal Trial Engineered With Room To Spare (NASDAQ:AURA)Seeking Alpha report covering Aura Biosciences Inc. (AURA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 14h ago
Aura Biosciences, Inc. Estimates – NASDAQ:AURATradingView report covering Aura Biosciences Inc. (AURA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Traders Daily • 17h ago
Precision Trading with Aura Biosciences Inc. (AURA) Risk ZonesStock Traders Daily report covering Aura Biosciences Inc. (AURA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREscanx.trade • 20h ago
Aura Biosciences CEO to speak at Morgan Stanley healthcare conferencescanx.trade report covering Aura Biosciences Inc. (AURA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 23h ago
AURA Q3'26 Earnings: revenue estimate is 0 USDTradingView report covering Aura Biosciences Inc. (AURA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Aura Biosciences (AURA) Edges Up 0.83% to $6.09, Holding Near Midpoint of Trading Range - Fibonacci Time Zonehttps://www.siam.in/ report covering Aura Biosciences Inc. (AURA) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AURA)
- ✓Walkthrough of AURA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AURA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.47%⚡ TESTING RESISTANCE
2026-11-02O $6.40H $6.40L $6.14C $6.14VOL 770.0K
RES: $6.44SUP: $5.33SMA50: $6.65SMA200: $6.72
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AURA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AURA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AURA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AURA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AURA)
Health Care Rank #803 of 1016
⚔️ SLBT vs AURA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AURA vs. SLBT, DBVT, CADL, IAM)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Aura Biosciences Inc. (AURA) ranks #803 by composite RQD confidence (31/100, grade E) and #411 by equity capitalization ($652.8M). Within this direct 5-issuer industry benchmark cohort, AURA leads on earnings valuation at N/A trailing P/E, while AURA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IAM currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with AURA at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AURA
ACTIVE
Aura Biosciences Inc. | E | 31/100 | — | — | -35.0% | -2.46% | $652.8M | Benchmark Subject |
| SLBT SL Science Holding Limited | D | 45/100 | — | — | — | +2.56% | $656.1M | /slbt-vs-aura → |
| DBVT DBV Technologies S.A. | E | 23/100 | — | — | -35.0% | -7.77% | $647.0M | /dbvt-vs-aura → |
| CADL Candel Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -3.70% | $661.9M | /cadl-vs-aura → |
| IAM Iambic Therapeutics Inc. | D | 49/100 | — | — | — | -5.95% | $676.9M | /iam-vs-aura → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001501796In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aura Biosciences Inc. (AURA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$106.2M, operating cash flow of -$84.7M, and free cash flow of -$85.2M (-5.1% YoY). On the balance sheet, AURA closed FY2025 with $169.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$106.2M | -$84.7M | -$85.2M | $169.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$86.9M | -$79.8M | -$81.1M | $182.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$76.4M | -$63.8M | -$63.8M | — | — |
3. AURA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Aura Biosciences Inc. (NASDAQ: AURA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $6.14 (-2.46% 1D, market cap $652.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AURA ranks #803 in composite RQD confidence.
How does AURA compare to SLBT and DBVT in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AURA carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SLBT (SL Science Holding Limited) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $656.1M) and DBVT (DBV Technologies S.A.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $647.0M). Among the 5-stock peer group, AURA leads on earnings multiple (N/A) while AURA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AURA?
Per AURA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001501796), Aura Biosciences Inc. generated $0 in revenue, -$106.2M in net income, and -$85.2M in free cash flow against $169.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AURA trading relative to its 50-day, 200-day, and 52-week technical levels?
AURA last traded at $6.14 (-2.46% on volume of 533,027 shares), positioning the stock -7.67% below its 50-day simple moving average ($6.65) and -8.63% below its 200-day simple moving average ($6.72). Across its 52-week range of $4.73 to $9.53, AURA sits at the 29.4% percentile with a 14-day RSI of 47.4 (NEUTRAL RANGE) and an implied next-earnings move of ±9.4% ($5.56 to $6.72).
AURA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AURA stock moving today?
Why AURA Stock dropped -2.46% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 31/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
AURA — Aura Biosciences Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:34:09Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, AURA carries an RQD Score of 31 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 7 / 20 (ROIC -35%; FCF yield -13.05%), Whale 13F Flow at 6 / 20 (institutional accumulation and options positioning), Insider Conviction at 3 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 5 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).
For a prospective investor, the weakest pillars are cash generation and insider conviction. Negative ROIC and negative FCF yield indicate the business is currently consuming capital rather than returning it, so any valuation case must rest on future cash flows that the source data does not project. The insider pillar scoring 3 / 20 signals limited insider-side conviction in the source's measure. The balance sheet pillar is the relative strength, with an Altman Z of 2.5 and Debt/Equity of 0.5, though a Piotroski F of 2/9 points to weak financial-health signals. Institutional and macro pillars are middling. The overall grade is a risk-screening output, not a price target; the upside case requires evidence of a cash-flow inflection that this dataset does not contain.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-112.8M | $-106.2M | N/A | $-85.2M | $59.5M | N/A |
| FY 2024 | $0.0M | $-96.1M | $-86.9M | N/A | $-81.1M | $31.7M | N/A |
| FY 2023 | $0.0M | $-85.0M | $-76.4M | N/A | $-63.8M | N/A | N/A |
Per the SEC financials, operating losses widened from $-85.0M in FY 2023 to $-112.8M in FY 2025, and cash rose from $31.7M to $59.5M over FY 2024–FY 2025. Gross, operating, and net margins are each reported as 0% per the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Not available in source data for debt figures in the financial table.
Recent Catalysts & News Wire Analysis
Per the recent news wire, the items are:
- A Yahoo Finance UK seasonal returns chart item (YELLOW, Market Wire).
- A Seeking Alpha piece titled "Aura Biosciences: A Pivotal Trial Engineered With Room To Spare" (YELLOW, Market Wire), indicating an upcoming pivotal trial.
- A TradingView estimates item (YELLOW, Market Wire).
- A Stock Traders Daily risk-zones item (RED, Risk Watch).
- A scanx.trade item stating the CEO will speak at a Morgan Stanley healthcare conference (YELLOW, Market Wire).
- A TradingView item listing a Q3'26 revenue estimate of 0 USD (YELLOW, Market Wire).
Per the Butterfly Supply-Chain Graph, supply_chain is NONE, with no butterfly links and no proprietary signals. The sole RED item is a risk-watch flag from a single trader-oriented source.
Open Questions
- What products or clinical programs drive the operating losses reported for FY 2023–FY 2025?
- What is the cash runway implied by $59.5M of cash against $-85.2M of FY 2025 free cash flow?
- What does the referenced pivotal trial measure, and what is its timing?
- What debt obligations exist, given the reported Debt/Equity of 0.5 but N/A debt figures?
- Why are EPS and P/E unavailable despite reported net losses?
AURA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Aura Biosciences Inc. (AURA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance UK • 8h ago
Aura Biosciences, Inc. (AURA) Seasonal returns chart Yahoo Finance UK report covering Aura Biosciences Inc. (AURA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 11h ago
Aura Biosciences: A Pivotal Trial Engineered With Room To Spare (NASDAQ:AURA) Seeking Alpha report covering Aura Biosciences Inc. (AURA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 14h ago
Aura Biosciences, Inc. Estimates – NASDAQ:AURA TradingView report covering Aura Biosciences Inc. (AURA) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Traders Daily • 17h ago
Precision Trading with Aura Biosciences Inc. (AURA) Risk Zones Stock Traders Daily report covering Aura Biosciences Inc. (AURA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE scanx.trade • 20h ago
Aura Biosciences CEO to speak at Morgan Stanley healthcare conference scanx.trade report covering Aura Biosciences Inc. (AURA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 23h ago
AURA Q3'26 Earnings: revenue estimate is 0 USD TradingView report covering Aura Biosciences Inc. (AURA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Aura Biosciences (AURA) Edges Up 0.83% to $6.09, Holding Near Midpoint of Trading Range - Fibonacci Time Zone https://www.siam.in/ report covering Aura Biosciences Inc. (AURA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
AURA Bull vs. Bear Conversation Board — What's Your Call at $6.14?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AURA 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $5.54 (-12.1%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is AURA (E • RQD 31/100) a Buy at $6.30?
Welcome to the AURA (Aura Biosciences Inc.) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $5.04 (-20.0%)
Spot @ $6.30 Pump the brakes on AURA — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on AURA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Aura Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $8.06 (+27.9%)
Spot @ $6.30 AURA cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on AURA, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $6.30 (52-wk range $4.73 - $9.53), any beat on forward guidance forces shorts and underweight funds to chase.